Esophageal Pathology — Barrett, Carcinoma, Varices

Barrett Esophagus

• Chronic GERD-induced mucosal injury: Prolonged acid exposure and bile reflux cause repeated epithelial ulceration and regeneration. The stratified squamous epithelium undergoes intestinal metaplasia, replacing native squamous mucosa with columnar epithelium containing goblet cells (mucus-secreting cells). This adaptive response paradoxically increases cancer risk by creating an unstable epithelial microenvironment. The squamocolumnar junction migrates proximally >3 cm above the gastroesophageal junction, creating a visible tongues of red mucosa on endoscopy.

• Molecular carcinogenesis cascade: Barrett epithelium accumulates sequential genetic mutations following the adenoma-carcinoma sequence (similar to colorectal cancer). Initial mutations in TP53 (p53 tumor suppressor) and CDKN2A (p16/INK4a cyclin-dependent kinase inhibitor) impair cell cycle checkpoints. Progressive aneuploidy develops, with loss of heterozygosity (LOH) at multiple loci. DNA methylation abnormalities (CpG island hypermethylation) silence tumor suppressors. Progression rates correlate with degree of dysplasia: non-dysplastic Barrett (0.2% annual progression), low-grade dysplasia (0.5-0.7% annually), and high-grade dysplasia (5-10% annually to invasive cancer).

• Inflammation-mediated carcinogenesis: Chronic acid injury triggers persistent nuclear factor-kappa B (NF-κB) activation and inflammatory cytokine production (IL-6, TNF-α, IL-8). This creates an oxidative stress microenvironment with elevated reactive oxygen species (ROS) promoting DNA damage. Cox-2 upregulation produces excessive prostaglandins, further promoting proliferation. The Barrett mucosa exhibits increased cell proliferation rates (measured by Ki-67 index) compared to normal squamous epithelium.

Esophageal Carcinoma - Squamous Cell Carcinoma (SCC)

• Field cancerization: Chronic carcinogens (tobacco, alcohol, caustic exposure, radiation) induce pan-esophageal mucosal changes. Multiple independent malignant clones develop, explaining synchronous or metachronous tumors. Acanthosis (squamous epithelial thickening) and dyskeratosis (abnormal keratinization) represent early dysplastic changes. SCC typically arises in the middle and lower thirds of the esophagus.

• Adenocarcinoma pathogenesis: Arises within Barrett esophagus through the metaplasia-dysplasia-carcinoma sequence above. Intestinal-type adenocarcinoma (from metaplastic columnar epithelium) represents ~60% of esophageal adenocarcinomas. Tumors often demonstrate signet-ring cell differentiation and mucinous features. Helicobacter pylori protective effect in Barrett progression (decreasing gastric acid production) explains increased adenocarcinoma incidence in developed nations with declining H. pylori prevalence.

Esophageal Varices

• Portal pressure gradient elevation: Portal hypertension (portal pressure >12 mmHg) creates hemodynamic stress on esophageal submucosal veins. These venous tributaries, normally low-pressure systems draining to the portal circulation, undergo progressive dilatation and tortuosity as portal pressure increases. Varices develop particularly at the gastroesophageal junction and lower third of esophagus where portosystemic anastomoses occur (between left gastric vein and azygos system). The esophageal venous plexus lacks surrounding muscular support, making vessels prone to rupture.

• Variceal wall deterioration: Endothelial dysfunction with reduced nitric oxide (NO) production impairs vasodilation and increases endothelial permeability. Angiogenic factors (VEGF, angiopoietin) promote abnormal neo-vascularization with friable, thin-walled vessels. The variceal wall becomes progressively thinned, with loss of the normal three-layered structure. Platelet dysfunction (from splenic sequestration in hypersplenism) and coagulopathy (from reduced clotting factor synthesis in cirrhosis) reduce hemostatic reserve. Bacterial translocation and infection increase inflammatory cytokine production, further destabilizing varices.

• Hemorrhage mechanism: Rupture occurs when wall tension exceeds wall strength. Laplace's Law (T = Pr, where tension equals pressure × radius) predicts that larger varices at higher pressures carry greater rupture risk. Increased intrathoracic pressure (straining, coughing, vomiting) acutely elevates variceal pressure. Mucosal erosion overlying varices creates direct vessel exposure to esophageal acid and bile.

Barrett Esophagus

• Chronic GERD (>10 years duration, daily symptoms)
• Male gender (2-3:1 ratio); Caucasian ethnicity (5-fold higher than African Americans)
• Age >50 years; Central obesity (increased intra-abdominal pressure)
• Smoking and alcohol use (independent carcinogens)
• Hiatus hernia (impaired lower esophageal sphincter function)
• Bile reflux (alkaline injury in addition to acid)

Esophageal Squamous Cell Carcinoma

• Tobacco smoking (20-fold increased risk; dose-dependent)
• Alcohol consumption (>40 g/day; synergistic with smoking via CYP2E1 acetaldehyde metabolism)
• Caustic ingestion (lye, alkali, acids; 10-20% progress to SCC over 20-40 years)
• Achalasia (chronic esophageal stasis, increased nitrosamine exposure)
• Previous mediastinal radiation (latency 10-20 years); head and neck malignancies (field effect)
• Chronic irritation: hot beverages, nutritional deficiencies (iron, vitamins A, E, zinc)
• Geographic variation: extremely high incidence in Iran, China, South Africa (associated with mycotoxins, nitrosamines, dietary factors)

Esophageal Adenocarcinoma

• Barrett esophagus (absolute risk 0.2-0.5% annually)
• Chronic GERD (even without Barrett diagnosis)
• Smoking and alcohol (less prominent than in SCC but still significant)
• Obesity (through GERD mechanism; BMI >30 increases risk 2-3 fold)
• Helicobacter pylori eradication (paradoxically increases risk by increasing gastric acid production)
• Male gender (8-10:1 male predominance)

Esophageal Varices

• Cirrhosis (90% of cases; any etiology—alcohol, viral hepatitis, NAFLD, biliary)
• Portal vein thrombosis (hypercoagulable states, prior pancreatitis)
• Schistosomiasis haematobium (endemic in parts of Africa and Middle East; causes portal fibrosis)
• Splenic vein thrombosis (pancreatitis, malignancy)
• Hemophilia and other coagulopathies (bleeding risk modifier)

Barrett Esophagus

• Asymptomatic in most cases; discovered during endoscopy for GERD evaluation
• Chronic heartburn and acid regurgitation (GERD symptoms that prompted investigation)
• Dysphagia (if stricture develops or high-grade dysplasia present)
• No specific physical examination findings (diagnosis requires histological confirmation)
• Endoscopic appearance: Salmon-pink or orange mucosa extending >3 cm above gastroesophageal junction, replacing normal pale squamous epithelium; may show intestinal metaplasia pattern with granular appearance

Esophageal Carcinoma

• Progressive dysphagia (initially solid foods, progressing to liquids and saliva; reflects luminal narrowing from tumor mass or stricture)
• Odynophagia (painful swallowing; indicates mucosal ulceration)
• Chest pain (substernal, pleuritic character; suggests mediastinal invasion)
• Weight loss (often >10 kg; multifactorial: dysphagia, cachexia from malignancy)
• Hoarseness and cough (left recurrent laryngeal nerve invasion from mid-esophageal tumors)
• Hematemesis or melena (from ulcerated tumor eroding into vessels)
• Physical exam findings: Weight loss, signs of metastatic disease (hepatomegaly, supraclavicular lymphadenopathy, ascites)
• Late presentation (~50% present with stage III-IV disease) due to submucous spread and delayed symptom onset

Esophageal Varices

• Hemoptysis or hematemesis (sudden, massive bleeding; patient may vomit coffee-ground material from acid-altered blood)
• Melena and hematochezia (dependent on bleeding rate and location)
• Shock symptoms (hypotension, tachycardia, syncope; reflects hypovolemia)
• Abdominal pain and distention (from variceal rupture or associated ascites)
• Physical examination findings:
• Spider angiomas (small vascular lesions with central arteriole and radiating branches; indicate portal hypertension)
• Palmar erythema (mottled redness of palms; from estrogen metabolism alterations)
• Jaundice (from hepatic dysfunction)
• Hepatosplenomegaly (cirrhotic liver often small and hard; spleen enlarged from portal congestion)
• Ascites (fluid wave, shifting dullness)
• Hemorrhoids and caput medusae (other portal hypertension manifestations)
• Acute presentation: Often with no prior warning; can progress to hepatic encephalopathy (asterixis, confusion) and hepatorenal syndrome if massive hemorrhage

Barrett Esophagus

• Upper endoscopy with targeted biopsies: Visualize salmon-pink mucosa >3 cm above gastroesophageal junction; biopsy at 2 cm intervals throughout extent of Barrett mucosa (Seattle protocol) to assess for dysplasia. Biopsies from apparent Barrett segment and squamocolumnar junction required for diagnosis.

• Histological findings (diagnostic gold standard):
• Columnar epithelium replacing squamous mucosa in the esophagus (normally only found in stomach/intestine)
• Intestinal metaplasia with goblet cells (mucus-secreting cells with characteristic cup-shaped, pale-staining cytoplasm containing mucinous material); goblet cells essential for diagnosis of specialized intestinal metaplasia Barrett
• Intact mucosa in non-dysplastic Barrett
• Low-grade dysplasia (LGD): Increased nuclear:cytoplasmic ratio, hyperchromatic nuclei, increased mitotic figures, but intact mucosal architecture with preserved columnar cells; nuclei confined to basal 50% of epithelium
• High-grade dysplasia (HGD): Nuclear abnormalities extend to surface; architectural distortion with cribriform or papillary patterns; loss of mucin-producing capacity; irregular glandular spacing
• Intestinal-type adenocarcinoma: Invasion through basement membrane into lamina propria or deeper; irregular glandular structures

• Gross appearance: Salmon or orange-red mucosa (due to columnar epithelium vascularity) demarcating sharply from pale squamous mucosa proximally; may show nodularity or ulceration if dysplasia present

• Length classification:
• Short-segment Barrett (<3 cm): lower cancer risk but still significant
• Long-segment Barrett (>3 cm): higher cancer risk, requires intensive surveillance

• Diagnostic criteria (Prague Criteria):
• C = circumferential extent (measured in cm)
• M = maximal extent (measured in cm from gastroesophageal junction)
• Example: C2M5 = 2 cm circumferential, extending to 5 cm above GE junction

Esophageal Carcinoma

• Ulcerating mass with irregular borders, erythematous granular surface
• Stricturing lesion causing luminal narrowing
• Friable, bleeding mucosa indicating ulceration
• Apple-core or napkin-ring appearance (circumferential lesions causing marked narrowing)

• Squamous cell carcinoma:
• Infiltrating nests, sheets, or cords of keratinizing squamous cells
• Intercellular bridges (desmosomes visible between cells, giving characteristic appearance)
• Pearl formation or keratinous pearls (concentric rings of keratinized material surrounded by neoplastic cells; highly characteristic)
• Marked nuclear pleomorphism and increased mitotic activity
• Depth of invasion assessed: mucosa (T1a), submucosa (T1b), muscularis propria (T2), adventitia (T3), structures beyond (T4)

• Adenocarcinoma:
• Glandular structures lined by mucin-producing cells with varying differentiation (well, moderate, or poorly differentiated)
• Signet-ring cell variant with displaced nuclei pushed to periphery by cytoplasmic mucin
• Mucinous adenocarcinoma with lakes of extracellular mucin
• Arising from Barrett esophagus (may see transition from specialized metaplasia to dysplasia to carcinoma in same specimen)
• Assessment of Lauren classification: intestinal type (glandular, cohesive) vs. diffuse type (signet-ring cells, infiltrative)

• CT chest with contrast: Evaluates tumor thickness (depth of invasion), mediastinal invasion, distant metastases (lung, liver, adrenal), lymph node involvement
• Endoscopic ultrasound (EUS): Superior to CT for T-staging (depth of invasion into esophageal wall layers); also enables fine-needle aspiration (FNA) of suspicious lymph nodes for tissue diagnosis
• PET-CT: Detects metabolically active metastases (brain, bone, distant lymph nodes)
• TNM staging based on:
• T-stage (depth): T1 (mucosa/submucosa), T2 (muscularis propria), T3 (adventitia), T4 (adjacent structures)
• N-stage: Number and location of involved lymph nodes (N0-N3)
• M-stage: Distant metastases (M0 vs. M1)

Esophageal Varices

• Dilated, tortuous vessels in esophageal

Acute variceal hemorrhage (emergency)

• Resuscitation first: two large-bore IVs, airway protection for ongoing hematemesis or encephalopathy. The AASLD portal hypertension guidance and Baveno consensus endorse a restrictive transfusion strategy targeting hemoglobin around 7 g/dL — over-transfusion raises portal pressure and precipitates rebleeding.
• Splanchnic vasoconstrictors: somatostatin analog — octreotide infusion — reduces splanchnic inflow and portal pressure; start before endoscopy and continue 3–5 days.
• Antibiotic prophylaxis: third-generation cephalosporin — ceftriaxone 1 g IV daily — is a mortality-reducing intervention in cirrhotic GI bleeding (AASLD), preventing SBP and bacteremia-driven rebleeding.
• Endoscopy within 12 hours: endoscopic variceal band ligation is definitive hemostasis; sclerotherapy is second-line. Refractory bleeding → balloon tamponade (Sengstaken–Blakemore) or covered esophageal stent as a bridge to TIPS. Early/pre-emptive TIPS is recommended in high-risk Child-Pugh B with active bleeding or Child-Pugh C.
• Prophylaxis: nonselective beta blocker — propranolol, nadolol, or carvedilol — for primary prophylaxis of medium/large varices; NSBB plus serial banding for secondary prophylaxis. Avoid selective beta blockers (no splanchnic effect).

Barrett esophagus (ACG guideline)

• Proton pump inhibitor: once-daily omeprazole for symptom and acid control, plus endoscopic surveillance at intervals set by dysplasia grade.
• Endoscopic eradication therapy — endoscopic mucosal/submucosal resection of visible nodules followed by radiofrequency ablation — is preferred over surveillance for confirmed low-grade dysplasia and is standard for high-grade dysplasia and intramucosal (T1a) cancer.
• Contraindicated/obsolete: esophagectomy as first-line for HGD; antireflux surgery does not abolish cancer risk and does not replace surveillance.

Invasive carcinoma (NCCN)

• T1a: endoscopic resection. Locally advanced (≥T2 or node-positive): neoadjuvant chemoradiation followed by esophagectomy; adjuvant immune checkpoint inhibitor (nivolumab) for residual disease.
• Metastatic/palliative: systemic chemotherapy with HER2 and PD-L1 testing; self-expanding stent or radiation for dysphagia.

Barrett esophagus

• Peptic stricture: fibrotic healing of chronic acid injury; signaled by slowly progressive dysphagia to solids with a smooth, tapered narrowing on endoscopy.
• Esophageal adenocarcinoma: stepwise dysplasia; signaled by nodularity or ulceration within the salmon-colored segment, or new weight loss.
• Treatment-related: post-radiofrequency ablation stricture, bleeding, and buried glands (metaplasia hidden beneath neosquamous epithelium, defeating surveillance); perforation after endoscopic resection.

Esophageal carcinoma

• Tracheoesophageal fistula: transmural tumor invasion into airway; signaled by coughing immediately on swallowing liquids and recurrent pneumonia — a management emergency requiring stenting.
• Aspiration pneumonia from retained esophageal contents.
• Recurrent laryngeal nerve invasion: hoarseness with vocal cord paralysis (mid-esophageal tumors).
• Massive hemorrhage from aortoesophageal erosion — exsanguinating emergency.
• Humoral hypercalcemia of malignancy via PTHrP, classically with squamous cell carcinoma: elevated calcium with suppressed PTH.
• Postoperative: anastomotic leak after esophagectomy (fever, tachycardia, leukocytosis, mediastinal air — emergency), chylothorax from thoracic duct injury, and stent migration or perforation.

Esophageal varices

• Exsanguinating hemorrhage: Laplace-driven rupture; hematemesis with shock — the primary emergency.
• Aspiration of blood: obtunded, actively vomiting cirrhotic; low threshold for intubation.
• Hepatic encephalopathy: intraluminal blood is a large nitrogen load; asterixis and confusion after a bleed.
• Spontaneous bacterial peritonitis and bacteremia: bacterial translocation post-bleed — the rationale for prophylactic ceftriaxone.
• Hepatorenal syndrome and ischemic hepatitis: hypoperfusion superimposed on cirrhosis; rising creatinine with bland urine sediment.
• Iatrogenic: post-banding ulcer bleeding and dysphagia; balloon tamponade causing pressure necrosis, esophageal rupture, or airway obstruction; TIPS shunting portal blood past hepatocytes, precipitating new or worsened encephalopathy and hepatic decompensation.

• Goblet cells are non-negotiable: intestinal metaplasia with goblet cells is required for Barrett esophagus in US (ACG) practice. Columnar mucosa without goblet cells is not Barrett on a Step 1 stem.
• Location splits the histology: adenocarcinoma sits in the distal third arising in Barrett; squamous cell carcinoma favors the middle third and is tied to smoking plus alcohol. A distal tumor in a chronic refluxer is adeno; a mid-esophageal tumor in a drinker/smoker is squamous.
• Single best next step for progressive solid-then-liquid dysphagia with weight loss is upper endoscopy with biopsy, not barium swallow. Barium (bird's beak) is the answer for suspected achalasia, and achalasia itself is a squamous carcinoma risk factor via chronic stasis.
• The association examiners love: squamous cell carcinoma → PTHrP-mediated hypercalcemia (high calcium, low PTH). Adenocarcinoma is not the paraneoplastic hypercalcemia answer.
• Variceal bleed algorithm: octreotide + prophylactic ceftriaxone + endoscopic band ligation within 12 hours; TIPS for failure. Antibiotics are a mortality-reducing step students routinely omit (AASLD).
• Transfusion trap: transfuse toward hemoglobin ~7 g/dL. "Transfuse to normalize hemoglobin" is the wrong choice — volume expansion raises portal pressure and worsens rebleeding.
• Beta blocker specificity: only nonselective agents (propranolol, nadolol, carvedilol) lower portal pressure by allowing unopposed splanchnic α-vasoconstriction. Metoprolol is the classic distractor.
• Retching-then-blood distractors: alcoholic with vomiting then hematemesis and a mucosal tear = Mallory–Weiss; with subcutaneous emphysema and mediastinal air = Boerhaave, a surgical emergency — neither is a varix.
• Counterintuitive association: H. pylori eradication and declining prevalence correlate with rising adenocarcinoma incidence via increased acid output.